MELBOURNE, Australia — November 10, 2025 — Leads & Copy — Propanc Biopharma, Inc. (Nasdaq: PPCB) has entered into a securities purchase agreement with Hexstone Capital LLC for a private placement of up to $100 million in convertible preferred stock. The funding will support Propanc’s digital asset acquisition strategy and accelerate its research and development pipeline, with a focus on its lead product candidate, PRP, entering a First-In-Human study in the second half of 2026.
Hexstone Capital LLC, a family office, has invested in numerous Digital Asset Treasury (DAT) companies across various digital assets, including BTC, ETH, SOL, DOGE, ATH, OG, and INJ.
Upon closing the agreement, Propanc received an initial investment of $1 million through the issuance of 100 shares of Series C Convertible Preferred Stock. Each share has a par value of $0.01 and a stated value of $10,000.
In addition, Propanc will issue 9,900 warrants to Hexstone, each allowing the purchase of one share of Preferred Stock at $10,000 per share, potentially generating up to $99 million in further funding. The warrants are immediately exercisable and remain valid for 12 months.
Subject to equity conditions and beneficial ownership limits, Propanc may call up to 500 warrants per calendar month at $0.01 each, allowing the exercise of up to $5 million in Preferred Stock per month, minus any warrants already exercised by Hexstone during that period.
James Nathanielsz, Propanc’s Chief Executive Officer, stated that the company is entering a transformative phase. He said the funding will help build the company’s digital asset base and strengthen its balance sheet, enabling it to accelerate its proenzyme technology to clinical development. Nathanielsz added that the company’s business model will revolutionize the way it funds and grows its intellectual property portfolio, fast-track R&D, and expand its development program to target metastatic cancer patients with solid tumors, and several chronic diseases.
Further details about the securities purchase agreement can be found in Propanc’s Form 8-K filed with the SEC and accessible at www.sec.gov.
Propanc Biopharma, Inc. is developing a novel approach to prevent recurrence and metastasis in cancer patients by targeting and eradicating cancer stem cells through the activation of proenzymes. The company’s lead product candidate, PRP, is designed to target the root cause of cancer proliferation and spread.
James Nathanielsz can be contacted at +61-3-9882-0780 or info@propanc.com.
Investor Relations can be contacted at irteam@propanc.com.
Source: Propanc Biopharma, Inc.
